This article was originally published in The Tan Sheet
Executive SummaryDouglas Burkett, PhD, named VP-pharmaceuticals & development May 2. Burkett will oversee Zila's Innovative Swab Technologies division and Zila Technical Operations, as well as Zila Pharmaceuticals, which includes the Phoenix-based company's professional and consumer pharmaceuticals businesses. Burkett began his career at Zila in 1995 as manager of research & manufacturing; he most recently served as VP of the Technical Operations division. Zila's products include Zilactin canker sore and oral pain remedies...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.